Select Page

PURA – Puration Confirms New Distribution Agreement With $4 Million Sales Potential and Schedules Presentation To Provide Further Details

PURA – Puration Confirms New Distribution Agreement With $4 Million Sales Potential and Schedules Presentation To Provide Further Details
559158.jpg

The new distributor is a supplier to a multibillion-dollar grocery chain.

DALLAS, Sept. 27, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Puration, Inc. (PURA) today confirmed the company had entered into a new European Distribution Agreement for PURA’s EVERx CBD Sports Water and other future CBD infused beverages com.

The agreement is anticipated to contribute $4 million in sales annually. The first shipment will go out to the new European Distributor next month. On Tuesday next week, October 1st, 2019, the PURA CEO will publish a presentation to provide more details on this exciting new distribution agreement.

The new distributor is a supplier to a multibillion-dollar grocery chain.

PURA last week kicked off a European marketing campaign for its EVERx CBD Sports Water at Arnold Schwarzenegger’s Arnold Sports Festival Europe in Barcelona. EVERx today is the leading CBD infused sports nutrition beverage with over $1 million in sales in 2018 and over $1 million in sales in the first six months of 2019 and targeting $4 million in sales by 2019-year end.

The EVERx CBD Sports Water distribution agreement announced today is part of a week-long series of PURA Corporate Updates.EVERx CBD Sports Water is available for purchase on line at www.USMJ.com hosted by PURA’s partner North American Cannabis Holdings, Inc. (USOTC: USMJ).For more information on Puration, visit http://www.purationinc.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

Leave a Reply

avatar

Join Our Newsletter

Get stock alerts, news & related alerts straight to your inbox!